Migraine Newswire (Page 8)

Migraine Newswire (Page 8)

Comprehensive Real-Time News Feed for Migraine. (Page 8)

Results 141 - 160 of 1,100 in Migraine

  1. Blind Tadpoles Learn Visually After Researchers Graft Eyes Onto Tails ...Read the original story

    Mar 30, 2017 | Newswise

    ... agonist drug were able to follow the rotating patterns. Importantly, this drug is currently in use for treatment of migraine in human patients, providing a proof-of-principle of repurposing neurotransmitter drugs for regenerative medicine in ...

    Comment?

  2. Global Migraine market is expected to grow at 6% CAGR during 2016-2022Read the original story w/Photo

    Mar 27, 2017 | World News Report

    Key Players - Allergan, Impax Laboratories, Eisai Inc., Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson, Klaria, Kowa Pharmaceuticals America,Luitpold Pharmaceuticals, Meda, Merck, " PUNE, MAHARASHTRA, INDIA, March 27, 2017 / EINPresswire.com / -- Market Highlights The global Migraine market has been evaluated as growing market and expected that the market will reach high growth figures. Migraine is a common neurovascular syndrome that is characterized by throbbing headaches and is commonly linked with other neurological symptoms, such as nausea, vomiting, and painful sensitivity to lights and sounds.

    Comment?

  3. Electronic patches for migraine headachesRead the original story w/Photo

    Mar 25, 2017 | Jerusalem Post

    Migraine sufferers usually take medications when their strong headaches begin, but there is a non-pharmacological way to cope with migraines, developed by a Rambam Medical Center physician and published in the journal Neurology a patch with electrodes attached to the arm. Migraines are unbearable, said Prof.

    Comment?

  4. Free public seminar in Portlaoise on migraineRead the original story w/Photo

    Mar 25, 2017 | Leinster Express

    On the 30th of March, 2017 at 7pm in the Maldron Hotel, Portlaoise, two key medical experts will present a FREE information seminar for adults and children who are suffering migraine. The seminar will be delivered by Consultant Paediatrician, Dr.Muhammed Tariq and Jane Melling, Clinical Nurse Specialist, Migraine Clinic, Dublin Neurological Institute, Mater Hospital Dublin An estimated 10% of children suffer migraine - that's over 100,000 children in Ireland alone.

    Comment?

  5. A critical review of manual therapy use for headache disorders:...Read the original story w/Photo

    Mar 23, 2017 | BioMed Central

    ... effective and coordinated care. ]. Respectively, they are the second and third most common disorders worldwide with migraine ranking as the seventh highest specific cause of disability globally [ Preventative migraine drug treatments include ...

    Comment?

  6. If you'd invested in: Bango and VernalisRead the original story w/Photo

    Mar 24, 2017 | MoneyWeek

    ... The shares have risen by more than 150% in the last 12 months. markets cough and cold medicine, antibiotics and migraine treatments in the US via its office in Pennsylvania, with more cough and cold products under development at its research centre ...

    Comment?

  7. Zosano Announces Closing Of Public Offering Of Common Stock And...Read the original story

    Mar 22, 2017 | BioSpace

    Zosano Pharma Corporation , an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the closing of the previously announced public offering of 19,550,000 shares of its common stock at a price of $1.50 per share, which includes the exercise in full by the underwriters of their over-allotment option to purchase up to 2,550,000 additional shares of common stock. The gross proceeds to Zosano from this offering are approximately $29.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Zosano.

    Comment?

  8. Headache pain: What to do when your head hurtsRead the original story w/Photo

    Mar 22, 2017 | The Washington Evening Journal

    ... and most often affect women. The pain can be severe, with pulsing and throbbing, and can last for several days. Migraine symptoms can also include blurry vision and nausea. "Migraines are complex and can be disabling," Porter says. Certain smells, ...

    Comment?

  9. Zosano Announces Pricing of Public Offering of Common StockRead the original story w/Photo

    Mar 17, 2017 | GlobeNewswire

    Zosano Pharma Corporation , an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the pricing of an underwritten public offering of 17,000,000 shares of its common stock at a price of $1.50 per share. All shares in the offering are being sold by Zosano, with expected gross proceeds to Zosano of $25.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Zosano.

    Comment?

  10. Minimally invasive treatment can safely relieve pain in children with severe migraineRead the original story w/Photo

    Mar 13, 2017 | Medical News

    A minimally invasive treatment for migraine headaches used for adults is also proving to be a safe and effective treatment for children and teenagers, and only takes minutes for a child to feel relief, according to new research presented at the Society of Interventional Radiology's 2017 Annual Scientific Meeting last week. Migraines are a common medical condition among youth and adults, affecting 12 percent of people ages 12 and older.

    Comment?

  11. Society Of Interventional Radiology Release: Innovative Treatment...Read the original story

    Mar 12, 2017 | BioSpace

    /PRNewswire-USNewswire/ -- A minimally invasive treatment for migraine headaches used for adults is also proving to be a safe and effective treatment for children and teenagers, and only takes minutes for a child to feel relief, according to new ...

    Comment?

  12. Two years after concussion, a chance at reliefRead the original story w/Photo

    Mar 8, 2017 | Denton Record-Chronicle

    ... Argyle and a sports and pain board-certified physician who specializes in interventional concussion management and migraine treatment. He said the SphenoCath's success rate is 90 percent, and many concussion sufferers, including Weatherford, are ...

    Comment?

  13. Unichem Labs gets USFDA nod for migraine tablets3 min agoRead the original story w/Photo

    Mar 8, 2017 | India.com

    New Delhi, Mar 8 Drug firm Unichem Laboratories said today it has received approval from the US health regulator for its Rizatriptan Benzoate tablets used for the treatment of migraine. The company "has received abbreviated new drug application approval from the United States Food and Drug Administration for Rizatriptan Benzoate ODT, 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg," Unichem Laboratories said in a filing to BSE.

    Comment?

  14. BRIEF-Unichem Labs gets FDA nod for migraine drugRead the original story w/Photo

    Mar 7, 2017 | Reuters

    * Says drug indicated for the acute treatment of migraine in adults and in pediatric patients 6 to 17 years of age Source text: bit.ly/2mWit4t Further company coverage: HERZOGENAURACH, March 8 The new boss of Adidas hiked sales and profit targets for ...

    Comment?

  15. APR Applied Pharma Research S.A. And Bring Innovative Migraine And Pain Treatment To Asian PatientsRead the original story

    Mar 5, 2017 | BioSpace

    BANGKOK & BALERNA, Switzerland-- --APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, is today proud to announce the business partnership with DKSH, the leading Market Expansion Services provider with a focus on Asia. The partnership involves marketing, sales, distribution and logistics for APR's patented Diclofenac 50 mg powder oral solution for acute migraine treatment and other pain areas, in Malaysia, the Philippines, Myanmar and Vietnam under the DKSH subsidiary Favorex.

    Comment?

  16. APR Applied Pharma Research and DKSH Bring Innovative Migraine and Pain Treatment to Asian PatientsRead the original story

    Mar 6, 2017 | Customer Interaction Solutions

    APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, is today proud to announce the business partnership with DKSH, the leading Market Expansion Services provider with a focus on Asia. The partnership involves marketing, sales, distribution and logistics for APR's patented Diclofenac 50 mg powder oral solution for acute migraine treatment and other pain areas, in Malaysia, the Philippines, Myanmar and Vietnam under the DKSH subsidiary Favorex.

    Comment?

  17. New effective treatment for children with migraineRead the original story

    Mar 5, 2017 | Newkerala.com

    Washington D.C.[USA], Mar. 6 : An effective treatment for migraine headaches used for adults is also proving to be a safe and effective treatment for children and teenagers, and only takes minutes for a child to feel relief. The research has been presented at the Society of Interventional Radiology's 2017 Annual Scientific Meeting.

    Comment?

  18. Innovative treatment offers relief to children with frequent migraine headachesRead the original story w/Photo

    Mar 5, 2017 | PhysOrg Weblog

    A minimally invasive treatment for migraine headaches used for adults is also proving to be a safe and effective treatment for children and teenagers, and only takes minutes for a child to feel relief, according to new research being presented today at the Society of Interventional Radiology's 2017 Annual Scientific Meeting. Migraines are a common medical condition among youth and adults, affecting 12 percent of people ages 12 and older.

    Comment?

  19. New Treatment May Ease Frequent Migraines in KidsRead the original story w/Photo

    Mar 4, 2017 | PsychCentral

    A minimally invasive treatment for migraine headaches used for adults is also proving to be a safe and effective treatment for children and teenagers, according to research presented at the Society of Interventional Radiology's 2017 Annual Scientific Meeting. Migraines affect 12 percent of people 12 and older.

    Comment?

  20. Veteran Biotech Executive Timothy S. Nelson Joins Impel's Board of DirectorsRead the original story

    Mar 3, 2017 | Customer Interaction Solutions

    ... Nelson led the company through its initial public offering and developed LEVADEX, an inhaled dihydroergotamine for migraine. Prior to MAP, he served as Senior Vice President of Commercial and Business Development at DURECT Corporation and has held ...

    Comment?